Title: | Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer |
Authors: | Kahraman, Seda Erul, Enes Seyyar, Mustafa Gümüşay, Özge Bayram, Ertuğrul Çakan Demirel, Burçin Acar, Ömer Aksoy, Sercan Baytemur, Naziyet Kose Sahin, Elif Cabuk, Devrim Basaran, Gül Paydas, Semra Yaren, Arzu Guven, Deniz Can Erdogan, Atike Pinar Demirci, Umut Yasar, Alper Bayoglu, Ibrahim Vedat Hizal, Mutlu Gulbagci, Burcu Paksoy, Nail Yilmaz, Funda Dogan, Ozlem Orhan, Sibel Oyucu Kayikcioglu, Erkan Aytac, Ali Keskinkilic, Merve Mocan, Eda Eylemer Unal, Olcun Umit Aydin, Esra Yucel, Hakan Isik, Deniz Eren, Onder Uluc, Basak Oyan Ozcelik, Melike Hacibekiroglu, Ilhan Aydiner, Adnan Demir, Hacer Oksuzoglu, Berna Cilbir, Ebru Cubukcu, Erdem Cetin, Bulent Oktay, Esin Erol, Cihan Okutur, Sadi Kerem Yildirim, Nilgun Alkan, Ali Selcukbiricik, Fatih Aksoy, Asude Karakas, Yusuf Ozkanli, Gulhan Duman, Berna Bozkurt Aydin, Dincer Dulgar, Ozgecan Er, Muhammed Muhiddin Teker, Fatih Yavuzsen, Tugba Aykan, Musa Baris Inal, Ali Iriagac, Yakup Kalkan, Nurhan Onal Keser, Murat Sakalar, Teoman Kut, Engin Bilgin, Burak Karaoglanoglu, Muge Sunar, Veli Ozdemir, Ozlem Turhal, Nazim Serdar Karadurmus, Nuri Yalcin, Bulent Sendur, Mehmet Ali Nahit |
Keywords: | CDK 4 6 inhibitors HER2-negative metastatic breast cancer HR-positive letrozole |
Publisher: | Future Medicine Ltd |
Abstract: | Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference. |
Description: | Article; Early Access |
URI: | https://doi.org/10.2217/fon-2022-1287 https://hdl.handle.net/11499/51149 |
ISSN: | 1479-6694 1744-8301 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
|